Fact CheckerSign in

NCT02143830RecruitingPhase 2

HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

A Phase II Trial of HSCT for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Risk-Adjusted Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine

Source: ClinicalTrials.gov · Last updated 12 Nov 2025

Brief summary (registry, in English)

The purpose of this study is to determine whether the use of lower doses of busulfan and the elimination of cyclosporine will further reduce transplant-related side effects for patients with Fanconi Anemia (FA). Patients will undergo a transplant utilizing mis-matched related or matched unrelated donors following a preparative regimen of busulfan, fludarabine, anti-thymocyte globulin and cyclophosphamide.

Status (registry)
Recruiting
Phase (registry)
Phase 2
Study type
Interventional
Enrollment
70 (estimated)
First submitted
28 Apr 2014
Start date
Apr 2014
Primary completion date
Dec 2026
Lead sponsor
Children's Hospital Medical Center, Cincinnati
NCT number
NCT02143830

What you commit to

  • Study type: Interventional · Phase 2
  • Planned participants: 70
  • From Apr 2014 to the primary completion date, Dec 2026
  • 3 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Active uncontrolled viral, bacterial or fungal infection
  • Patient seropositive for HIV-I/II; HTLV -I/II

Lab values

  • Female patients who are pregnant (positive serum or urine HCG) or breast-feeding.

Other

  • Active CNS leukemia

Who the study is looking for

  • Patients must have a diagnosis of Fanconi anemia
  • Patients must have one of the following hematologic diagnoses:
    • Severe Aplastic Anemia (SAA), with bone marrow cellularity of \<25% OR Severe Isolated Single Lineage Cytopenia and at least one of the following features:
    • Platelet count \<20 x 109/L or platelet transfusion dependence\*
    • ANC \<1000 x 109/L
    • Hgb \<8 gm/dl or red cell transfusion dependence\*
    • Myelodysplastic Syndrome (MDS) (based on WHO or IPSS Classification
    • Acute Myelogenous Leukemia (untreated, in remission or with refractory or relapsed disease)
  • Donors will be either human leukocyte antigen (HLA) compatible unrelated or HLA-genotypically matched related donors (no fully matched sibling donor).
  • Patients and donors may be of either gender or any ethnic background.
  • Patients must have a Karnofsky adult, or Lansky pediatric performance scale status \> 70%.
  • Patients must have adequate physical function measured by:
    • Cardiac: asymptomatic or if symptomatic then 1) left ventricular ejection fraction (LVEF) at rest must be \> 50% and must improve with exercise or 2) Shortening Fraction \> 29%
    • Hepatic: \< 5 x upper limit of normal (ULN) alanine transaminase (ALT) and \< 2.0 mg/dl total serum bilirubin.
    • Renal: serum creatinine \<1.5 mg/dl or if serum creatinine is outside the normal range, then CrCl \> 50 ml/min/1.73 m2
    • Pulmonary: asymptomatic or if symptomatic, DLCO \> 50% of predicted
  • Each patient must be willing to participate as a research subject and must sign an informed consent form.
  • Female patients and donors must not be pregnant or breastfeeding at the time of signing consent. Women must be willing to undergo a pregnancy test prior to transplant and avoid becoming pregnant while on study.

Age in the registry: 3 months to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (3)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Cincinnati Children's Hospital Medical Center
Coordinator of this site? Confirm its status
CincinnatiUnited StatesRecruiting
Memorial Sloan-Kettering Cancer Center
Coordinator of this site? Confirm its status
New YorkUnited StatesCompleted
Fred Hutchinson Cancer Research Center
Coordinator of this site? Confirm its status
SeattleUnited StatesRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.